Loading…
PSAT106 Infigratinib in Children with Achondroplasia: Design of the PROPEL, PROPEL2 and PROPEL OLE Studies
Saved in:
Published in: | Journal of the Endocrine Society 2022-11, Vol.6 (Supplement_1), p.A633-A633 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | A633 |
container_issue | Supplement_1 |
container_start_page | A633 |
container_title | Journal of the Endocrine Society |
container_volume | 6 |
creator | Muslimova, Elena De Bergua, Josep Maria Savarirayan, Ravi Arundel, Paul McDevitt, Helen Cormier-Daire, Valerie Saraff, Vrinda Skae, Mars Delgado, Borja Leiva-Gea, Antonio Santos-Simarro, Fernando Pierre Salles, Jean Nicolino, Marc Rossi, Massimiliano Kannu, Peter Bober, Michael B Phillips III, John Saal, Howard Harmatz, Paul Burren, Christine Gotway, Garrett Cho, Terry Weng, Richard Rogoff, Daniela Hoover-Fong, Julie Irving, Melita |
description | |
doi_str_mv | 10.1210/jendso/bvac150.1311 |
format | article |
fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1210_jendso_bvac150_1311</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1210_jendso_bvac150_1311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c891-e284dc1e4efb7432a41f551a4cbb121033908d7212b2d5b1e6fd3d03492fbe6f3</originalsourceid><addsrcrecordid>eNpNkN1KwzAcxYMoOOaewJs8gHX5J-naejfqnIPCiut9SZpkTZnpSKri29uxXnh1Pi4OnB9Cj0CegQJZdtqp0C_lt2ggHjsGcINmlCc0giyht__8PVqE0BFCIGM843yGuvKwroCs8M4Ze_RisM5KbB3OW3tSXjv8Y4cWr5u2d8r355MIVrzgVx3s0eHe4KHVuPzYl5viaVKKhVOTx_tigw_Dl7I6PKA7I05BLyado-ptU-XvUbHf7vJ1ETVpBpGmKVcNaK6NTDijgoOJYxC8kfJyl7GMpCqhQCVVsQS9MoopMt6hRo6BzRG7zja-D8FrU5-9_RT-twZSXxbqK7B6AlZfgLE_4cNe4A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>PSAT106 Infigratinib in Children with Achondroplasia: Design of the PROPEL, PROPEL2 and PROPEL OLE Studies</title><source>Oxford Journals Open Access Collection</source><source>PubMed Central</source><creator>Muslimova, Elena ; De Bergua, Josep Maria ; Savarirayan, Ravi ; Arundel, Paul ; McDevitt, Helen ; Cormier-Daire, Valerie ; Saraff, Vrinda ; Skae, Mars ; Delgado, Borja ; Leiva-Gea, Antonio ; Santos-Simarro, Fernando ; Pierre Salles, Jean ; Nicolino, Marc ; Rossi, Massimiliano ; Kannu, Peter ; Bober, Michael B ; Phillips III, John ; Saal, Howard ; Harmatz, Paul ; Burren, Christine ; Gotway, Garrett ; Cho, Terry ; Weng, Richard ; Rogoff, Daniela ; Hoover-Fong, Julie ; Irving, Melita</creator><creatorcontrib>Muslimova, Elena ; De Bergua, Josep Maria ; Savarirayan, Ravi ; Arundel, Paul ; McDevitt, Helen ; Cormier-Daire, Valerie ; Saraff, Vrinda ; Skae, Mars ; Delgado, Borja ; Leiva-Gea, Antonio ; Santos-Simarro, Fernando ; Pierre Salles, Jean ; Nicolino, Marc ; Rossi, Massimiliano ; Kannu, Peter ; Bober, Michael B ; Phillips III, John ; Saal, Howard ; Harmatz, Paul ; Burren, Christine ; Gotway, Garrett ; Cho, Terry ; Weng, Richard ; Rogoff, Daniela ; Hoover-Fong, Julie ; Irving, Melita</creatorcontrib><identifier>ISSN: 2472-1972</identifier><identifier>EISSN: 2472-1972</identifier><identifier>DOI: 10.1210/jendso/bvac150.1311</identifier><language>eng</language><ispartof>Journal of the Endocrine Society, 2022-11, Vol.6 (Supplement_1), p.A633-A633</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Muslimova, Elena</creatorcontrib><creatorcontrib>De Bergua, Josep Maria</creatorcontrib><creatorcontrib>Savarirayan, Ravi</creatorcontrib><creatorcontrib>Arundel, Paul</creatorcontrib><creatorcontrib>McDevitt, Helen</creatorcontrib><creatorcontrib>Cormier-Daire, Valerie</creatorcontrib><creatorcontrib>Saraff, Vrinda</creatorcontrib><creatorcontrib>Skae, Mars</creatorcontrib><creatorcontrib>Delgado, Borja</creatorcontrib><creatorcontrib>Leiva-Gea, Antonio</creatorcontrib><creatorcontrib>Santos-Simarro, Fernando</creatorcontrib><creatorcontrib>Pierre Salles, Jean</creatorcontrib><creatorcontrib>Nicolino, Marc</creatorcontrib><creatorcontrib>Rossi, Massimiliano</creatorcontrib><creatorcontrib>Kannu, Peter</creatorcontrib><creatorcontrib>Bober, Michael B</creatorcontrib><creatorcontrib>Phillips III, John</creatorcontrib><creatorcontrib>Saal, Howard</creatorcontrib><creatorcontrib>Harmatz, Paul</creatorcontrib><creatorcontrib>Burren, Christine</creatorcontrib><creatorcontrib>Gotway, Garrett</creatorcontrib><creatorcontrib>Cho, Terry</creatorcontrib><creatorcontrib>Weng, Richard</creatorcontrib><creatorcontrib>Rogoff, Daniela</creatorcontrib><creatorcontrib>Hoover-Fong, Julie</creatorcontrib><creatorcontrib>Irving, Melita</creatorcontrib><title>PSAT106 Infigratinib in Children with Achondroplasia: Design of the PROPEL, PROPEL2 and PROPEL OLE Studies</title><title>Journal of the Endocrine Society</title><issn>2472-1972</issn><issn>2472-1972</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpNkN1KwzAcxYMoOOaewJs8gHX5J-naejfqnIPCiut9SZpkTZnpSKri29uxXnh1Pi4OnB9Cj0CegQJZdtqp0C_lt2ggHjsGcINmlCc0giyht__8PVqE0BFCIGM843yGuvKwroCs8M4Ze_RisM5KbB3OW3tSXjv8Y4cWr5u2d8r355MIVrzgVx3s0eHe4KHVuPzYl5viaVKKhVOTx_tigw_Dl7I6PKA7I05BLyado-ptU-XvUbHf7vJ1ETVpBpGmKVcNaK6NTDijgoOJYxC8kfJyl7GMpCqhQCVVsQS9MoopMt6hRo6BzRG7zja-D8FrU5-9_RT-twZSXxbqK7B6AlZfgLE_4cNe4A</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Muslimova, Elena</creator><creator>De Bergua, Josep Maria</creator><creator>Savarirayan, Ravi</creator><creator>Arundel, Paul</creator><creator>McDevitt, Helen</creator><creator>Cormier-Daire, Valerie</creator><creator>Saraff, Vrinda</creator><creator>Skae, Mars</creator><creator>Delgado, Borja</creator><creator>Leiva-Gea, Antonio</creator><creator>Santos-Simarro, Fernando</creator><creator>Pierre Salles, Jean</creator><creator>Nicolino, Marc</creator><creator>Rossi, Massimiliano</creator><creator>Kannu, Peter</creator><creator>Bober, Michael B</creator><creator>Phillips III, John</creator><creator>Saal, Howard</creator><creator>Harmatz, Paul</creator><creator>Burren, Christine</creator><creator>Gotway, Garrett</creator><creator>Cho, Terry</creator><creator>Weng, Richard</creator><creator>Rogoff, Daniela</creator><creator>Hoover-Fong, Julie</creator><creator>Irving, Melita</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221101</creationdate><title>PSAT106 Infigratinib in Children with Achondroplasia: Design of the PROPEL, PROPEL2 and PROPEL OLE Studies</title><author>Muslimova, Elena ; De Bergua, Josep Maria ; Savarirayan, Ravi ; Arundel, Paul ; McDevitt, Helen ; Cormier-Daire, Valerie ; Saraff, Vrinda ; Skae, Mars ; Delgado, Borja ; Leiva-Gea, Antonio ; Santos-Simarro, Fernando ; Pierre Salles, Jean ; Nicolino, Marc ; Rossi, Massimiliano ; Kannu, Peter ; Bober, Michael B ; Phillips III, John ; Saal, Howard ; Harmatz, Paul ; Burren, Christine ; Gotway, Garrett ; Cho, Terry ; Weng, Richard ; Rogoff, Daniela ; Hoover-Fong, Julie ; Irving, Melita</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c891-e284dc1e4efb7432a41f551a4cbb121033908d7212b2d5b1e6fd3d03492fbe6f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Muslimova, Elena</creatorcontrib><creatorcontrib>De Bergua, Josep Maria</creatorcontrib><creatorcontrib>Savarirayan, Ravi</creatorcontrib><creatorcontrib>Arundel, Paul</creatorcontrib><creatorcontrib>McDevitt, Helen</creatorcontrib><creatorcontrib>Cormier-Daire, Valerie</creatorcontrib><creatorcontrib>Saraff, Vrinda</creatorcontrib><creatorcontrib>Skae, Mars</creatorcontrib><creatorcontrib>Delgado, Borja</creatorcontrib><creatorcontrib>Leiva-Gea, Antonio</creatorcontrib><creatorcontrib>Santos-Simarro, Fernando</creatorcontrib><creatorcontrib>Pierre Salles, Jean</creatorcontrib><creatorcontrib>Nicolino, Marc</creatorcontrib><creatorcontrib>Rossi, Massimiliano</creatorcontrib><creatorcontrib>Kannu, Peter</creatorcontrib><creatorcontrib>Bober, Michael B</creatorcontrib><creatorcontrib>Phillips III, John</creatorcontrib><creatorcontrib>Saal, Howard</creatorcontrib><creatorcontrib>Harmatz, Paul</creatorcontrib><creatorcontrib>Burren, Christine</creatorcontrib><creatorcontrib>Gotway, Garrett</creatorcontrib><creatorcontrib>Cho, Terry</creatorcontrib><creatorcontrib>Weng, Richard</creatorcontrib><creatorcontrib>Rogoff, Daniela</creatorcontrib><creatorcontrib>Hoover-Fong, Julie</creatorcontrib><creatorcontrib>Irving, Melita</creatorcontrib><collection>CrossRef</collection><jtitle>Journal of the Endocrine Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Muslimova, Elena</au><au>De Bergua, Josep Maria</au><au>Savarirayan, Ravi</au><au>Arundel, Paul</au><au>McDevitt, Helen</au><au>Cormier-Daire, Valerie</au><au>Saraff, Vrinda</au><au>Skae, Mars</au><au>Delgado, Borja</au><au>Leiva-Gea, Antonio</au><au>Santos-Simarro, Fernando</au><au>Pierre Salles, Jean</au><au>Nicolino, Marc</au><au>Rossi, Massimiliano</au><au>Kannu, Peter</au><au>Bober, Michael B</au><au>Phillips III, John</au><au>Saal, Howard</au><au>Harmatz, Paul</au><au>Burren, Christine</au><au>Gotway, Garrett</au><au>Cho, Terry</au><au>Weng, Richard</au><au>Rogoff, Daniela</au><au>Hoover-Fong, Julie</au><au>Irving, Melita</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PSAT106 Infigratinib in Children with Achondroplasia: Design of the PROPEL, PROPEL2 and PROPEL OLE Studies</atitle><jtitle>Journal of the Endocrine Society</jtitle><date>2022-11-01</date><risdate>2022</risdate><volume>6</volume><issue>Supplement_1</issue><spage>A633</spage><epage>A633</epage><pages>A633-A633</pages><issn>2472-1972</issn><eissn>2472-1972</eissn><doi>10.1210/jendso/bvac150.1311</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2472-1972 |
ispartof | Journal of the Endocrine Society, 2022-11, Vol.6 (Supplement_1), p.A633-A633 |
issn | 2472-1972 2472-1972 |
language | eng |
recordid | cdi_crossref_primary_10_1210_jendso_bvac150_1311 |
source | Oxford Journals Open Access Collection; PubMed Central |
title | PSAT106 Infigratinib in Children with Achondroplasia: Design of the PROPEL, PROPEL2 and PROPEL OLE Studies |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T22%3A12%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PSAT106%20Infigratinib%20in%20Children%20with%20Achondroplasia:%20Design%20of%20the%20PROPEL,%20PROPEL2%20and%20PROPEL%20OLE%20Studies&rft.jtitle=Journal%20of%20the%20Endocrine%20Society&rft.au=Muslimova,%20Elena&rft.date=2022-11-01&rft.volume=6&rft.issue=Supplement_1&rft.spage=A633&rft.epage=A633&rft.pages=A633-A633&rft.issn=2472-1972&rft.eissn=2472-1972&rft_id=info:doi/10.1210/jendso/bvac150.1311&rft_dat=%3Ccrossref%3E10_1210_jendso_bvac150_1311%3C/crossref%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c891-e284dc1e4efb7432a41f551a4cbb121033908d7212b2d5b1e6fd3d03492fbe6f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |